Irritability
25
8
9
10
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 25 trials
100.0%
+13.5% vs benchmark
16%
4 trials in Phase 3/4
30%
3 of 10 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 10 completed trials
Clinical Trials (25)
Psychological Treatments for Youth With Severe Irritability.
A Scalable Trans Diagnostic Intervention Targeting Adolescent Agency Supported by Conversational AI (AGENCIA)
Study Brain Mechanisms of Frustration With Magnetoencephalography in Healthy Volunteers
Teen Vulnerability to Irritability: Brain and Estrogen Changes
Predictors of Improvements in Irritability and Aggression in Children With ADHD Treated With CNS Stimulants
Behavioral Parent Training With and Without AI Support for Children With Disruptive Behaviors
Fluoxetine on Emotional Experience (FLEX) Study
Behavior Therapy for Irritability in Autism
Implementation of the Pain and Irritability of Unknown Origin (PIUO) Pathway in Community Pediatric Practices
AP Metabolism Transcriptomics
Efficacy of Gabapentin in Treating Pain in Children With SNI (Gabapentin Trial)
Pain and Irritability in Non-Verbal Children
Evaluating the Efficacy of Dextromethorphan/Quinidine in Treating Irritability in Huntington's Disease
Cognitive-Behavioral Therapy for Disruptive Behavior in Children and Adolescents
Nicotinic Cholinergic Modulation as a Novel Treatment Strategy for Aggression Associated With Autism
Telepsychoeducation for the Prevention of Emotional Distress in Professionals and Students From Essential Services in the Context of COVID-19
Attention Bias Modification, Attention Control and Psychoeducation for Irritability in Children and Adolescents
Safety Study of a Rotavirus Vaccine (Rotavin-M1) Among Healthy Adults
A Dose-escalating Study to Evaluate the Immunogenicity and Safety of Rotavin-M1 Vaccine in Healthy Infants
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy